1-9 of 9
Sandrine Puverel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade

Matthew G. Mei, Lu Chen, Sandrine Puverel, L. Elizabeth Budde, Swetha Kambhampati, Shari Daniels, Bev Dunning, Melissa Banez, Larry W. Kwak, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 1697.
https://doi.org/10.1182/blood-2023-190753
Published: 2023
Journal Articles

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

L. Elizabeth Budde, Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Swetha Kambhampati, Alan Macias, Teresa Kim, Sylvia Dulan, Baishakhi Barva, Sandrine Puverel, Katrin Tiemann, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak
Journal: Blood
Blood (2023) 142 (Supplement 1): 221.
https://doi.org/10.1182/blood-2023-183032
Published: 2023
Journal Articles

Safety, Efficacy and T-Cell Predictive Biomarkers in a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey P. Shouse, Leslie L. Popplewell, Alex Muir, Tanya Siddiqi, Alex F. Herrera, Olga Danilova, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S Davids, Alexey Danilov
Journal: Blood
Blood (2023) 142 (Supplement 1): 1730.
https://doi.org/10.1182/blood-2023-182559
Published: 2023
Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Clinical Trials & Observations
Matthew Mei, Lu Chen, James Godfrey, Joo Song, Colt Egelston, Sandrine Puverel, L. Elizabeth Budde, Saro Armenian, Liana Nikolaenko, Mary Nwangwu, Weihua Guo, Lei Gao, Peter Lee, Robert Chen, Shari Daniels, Neena Kennedy, Lacolle Peters, Jasmine Zain, Steven Rosen, Stephen Forman, Leslie Popplewell, Larry Kwak, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (16): 1359–1370.
https://doi.org/10.1182/blood.2023020485
Published: 2023
Includes: Supplemental data
Journal Articles

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey Shouse, Tanya Siddiqi, Leslie L. Popplewell, Alexandra Muir, Ivana Melgar, Kirsten Orand, Brandy Gonzalez, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V Danilov
Journal: Blood
Blood (2022) 140 (Supplement 1): 6633–6634.
https://doi.org/10.1182/blood-2022-160157
Published: 2022
Journal Articles

A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

Alexey V Danilov, Alexandra Muir, Ivana Melgar, Sandrine Puverel, Peter Sportelli, Hari P. Miskin, Lu Chen, Geoffrey Shouse
Journal: Blood
Blood (2022) 140 (Supplement 1): 3633–3634.
https://doi.org/10.1182/blood-2022-159805
Published: 2022
Journal Articles

Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma

Swetha Kambhampati, Matthew Mei, Lu Chen, Sandrine Puverel, Robert Chen, Leslie L. Popplewell, Liana Nikolaenko, Lacolle Peters, Saro H. Armenian, Larry W. Kwak, Steve T Rosen, Stephen J Forman, Alex F. Herrera
Journal: Blood
Blood (2022) 140 (Supplement 1): 9418–9419.
https://doi.org/10.1182/blood-2022-157623
Published: 2022
Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Alex F. Herrera, Lu Chen, Jennifer L. Crombie, Jonathon B. Cohen, Ranjana H. Advani, Ann S. LaCasce, Leslie L. Popplewell, Sandrine Puverel, Lacolle Peters, Shari Daniels, James Godfrey, Geoffrey Shouse, Matthew Mei, Swetha Kambhampati, L. Elizabeth Budde, Liana Nikolaenko, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Matthew J. Matasar
Journal: Blood
Blood (2022) 140 (Supplement 1): 1065–1067.
https://doi.org/10.1182/blood-2022-165699
Published: 2022
Journal Articles

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey Shouse, Tanya Siddiqi, Leslie L. Popplewell, Alexandra Muir, Ivana Melgar, Brandy Gonzales, Kirsten Orand, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V. Danilov
Journal: Blood
Blood (2021) 138 (Supplement 1): 3558.
https://doi.org/10.1182/blood-2021-149320
Published: 2021